Proposed Data Collection Submitted for Public Comment and Recommendations, 10853-10855 [2018-05000]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 49 / Tuesday, March 13, 2018 / Notices
Basswood Partners, LLC, Basswood
Enhanced Long Short GP, LLC, and
Basswood Capital Management, LLC; all
of New York, New York; to retain and
acquire voting shares of American River
Bankshares, Rancho Cordova,
California, and thereby indirectly retain
and acquire shares of American River
Bank, Sacramento, California.
Board of Governors of the Federal Reserve
System, March 7, 2018.
Ann E. Misback,
Secretary of the Board.
BILLING CODE P
amozie on DSK30RV082PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than April 10, 2018.
A. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. RCB Holding Company, Inc.,
Claremore, Oklahoma; to acquire 100
percent of the voting shares of Central
Bank and Trust Co., Hutchinson,
Kansas.
Jkt 244001
BILLING CODE P
Proposed Data Collection Submitted
for Public Comment and
Recommendations
FEDERAL RESERVE SYSTEM
17:47 Mar 12, 2018
[FR Doc. 2018–05010 Filed 3–12–18; 8:45 am]
[60Day–2018–1091; Docket No. CDC–2018–
0022]
[FR Doc. 2018–04953 Filed 3–12–18; 8:45 am]
VerDate Sep<11>2014
Board of Governors of the Federal Reserve
System, March 8, 2018.
Ann E. Misback,
Secretary of the Board.
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled ’’Using Qualitative Methods to
Understand Issues in HIV Prevention,
Care and Treatment in the United
States.’’ CDC’s goal for this generic
information collection mechanism is to
conduct qualitative studies to quickly
identify barriers and facilitators to HIV
prevention, care and treatment in
specific regions with high HIV burden
in the US.
DATES: CDC must receive written
comments on or before May 14, 2018.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2018–
0022 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
SUMMARY:
Please note: Submit all comments through
the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
10853
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Leroy A.
Richardson, Information Collection
Review Office, Centers for Disease
Control and Prevention, 1600 Clifton
Road, NE, MS–D74, Atlanta, Georgia
30329; phone: 404–639–7570; Email:
omb@cdc.gov.
SUPPLEMENTARY INFORMATION:
Under the Paperwork Reduction Act
of 1995 (PRA) (44 U.S.C. 3501–3520),
Federal agencies must obtain approval
from the Office of Management and
Budget (OMB) for each collection of
information they conduct or sponsor. In
addition, the PRA also requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each new proposed
collection, each proposed extension of
existing collection of information, and
each reinstatement of previously
approved information collection before
submitting the collection to the OMB for
approval. To comply with this
requirement, we are publishing this
notice of a proposed data collection as
described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
FOR FURTHER INFORMATION CONTACT:
Proposed Project
Using Qualitative Methods to
Understand Issues in HIV Prevention,
Care and Treatment in the United States
(OMB Control Number 0920–1091;
expires 12/31/2018)—Extension—
National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention,
Centers for Disease Control and
Prevention (CDC).
E:\FR\FM\13MRN1.SGM
13MRN1
10854
Federal Register / Vol. 83, No. 49 / Tuesday, March 13, 2018 / Notices
Background and Brief Description
The CDC’s National Center on HIV/
AIDS, Viral Hepatitis, STD and TB
Prevention (NCHHSTP), Division of
HIV/AIDS Prevention (DHAP) seeks a
three–year extension to conduct
qualitative studies to quickly identify
barriers and facilitators to HIV
prevention, care and treatment in
specific regions with high HIV burden
in the US. Proposed activities remain
consistent with the national HIV
prevention goals, the CDC Division of
HIV/AIDS Prevention (DHAP) Strategic
Plan, and DHAP’s High-impact HIV
Prevention approach.
The purposes for each data collection
study supported under this umbrella
generic information collection plan will
be to understand specific barriers and
facilitators to local HIV prevention, care
and treatment in the United States and
territories. For example, each study will
seek to identify ways to improve
programmatic activities along the
continuum of HIV prevention, treatment
and care for different populations
residing in different geographic settings
with greatest burden of HIV.
The target populations for the studies
include, but are not limited to: (1)
Persons living with HIV who are in
treatment; (2) persons living with HIV
who are out of treatment and who may
or may not be seeking treatment at
healthcare facilities; (3) persons at high
risk for HIV acquisition (HIV negative)
and HIV transmission (HIV positive); (4)
persons from groups at high risk for HIV
including gay, bisexual and other MSM,
transgender persons, and injection and
non-injection drug users; (5) persons
from racial and ethnic minorities; and
(6) healthcare providers or other
professionals who provide HIV
prevention, care and treatment services.
Other populations may include
individuals who provide non-HIV
services or otherwise interact with
persons living with HIV or persons at
risk for HIV acquisition.
Studies will only provide local
contextual information about the
barriers and facilitators to HIV
prevention, care, and treatment
experienced by specific communities at
risk for acquiring HIV infection, by HIVpositive persons across the HIV care
continuum, and by organizations or
individuals providing HIV prevention,
care, treatment, and related support
services.
Data collection methods used in any
of the specific studies primarily will
consist of rapid qualitative assessment
methodologies, such as semi-structured
and in-depth qualitative interviews,
focus groups; direct observations;
document reviews; and short structured
surveys. Data will be analyzed using
well-established qualitative analysis
methods, such as coding interviews for
themes about barriers and successes to
HIV prevention, care, and treatment.
Structured response surveys will be
analyzed using descriptive statistics and
other appropriate statistical methods.
CDC will use the results from each
specific data collection study to help
identify ways to improve local
programmatic activities for specific
communities along the continuum of
HIV prevention, treatment and care for
populations and areas with the greatest
HIV burden. CDC will communicate
study outcomes to local stakeholders
and organizations in positions to
consider and implement site-specific
Type of respondents
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Average
burden per
response
(in hours)
Number of
responses per
respondent
Total burden
(in hours)
.....................
.....................
.....................
.....................
.....................
.....................
.....................
Study Screener ................................
Contact Information Form ................
Consent Form ..................................
Demographic Survey ........................
Interview Guide ................................
Provider Demographic Survey .........
Provider Interview Guide ..................
1,600
600
600
500
500
100
100
1
1
1
1
1
1
1
5/60
1/60
5/60
15/60
1
15/60
45/60
133
10
50
125
500
25
75
Total ...........................................
amozie on DSK30RV082PROD with NOTICES
General
General
General
General
General
General
General
Number of
respondents
Form name
improvements in HIV prevention, care,
and treatment for each of the study sites
examined. For stakeholders,
organizations, or agencies outside the
local affected communities, all
communications will include clear
discussion of the limitations of the
region-specific, qualitative methods and
the non-generalizability of the study
outcomes.
For a given year, each separate data
collection will range from 30
(minimum) to 200 (maximum)
respondents, based on the nature and
scope of the research purposes. For
example, if there are three data
collections, the maximum combined
number of expected respondents is 600.
In a given year, CDC anticipates the
need to screen 1,600 persons to identify
800 eligible persons, of which 600
persons will agree to participate.
CDC anticipates that screener forms
will take 5 minutes to complete each,
contact information forms will take 1
minute to complete each, and consent
forms will take 5 minutes to complete
each. CDC anticipates study eligibility
for 50 percent of the targeted
populations screened. Of eligible
persons, 75% will agree to participate.
Brief structured surveys will take 15
minutes to complete. In-depth
interviews or focus groups with
respondents are expected to take 60
minutes (1 hour) to complete. In-depth
interviews or focus groups with
healthcare providers are expected to
take 45 minutes to complete.
The total annual response burden,
based on an average of 600 study
respondents per year (assuming three
large data collections involving 200
participants each), is 918 hours.
...........................................................
........................
........................
........................
918
VerDate Sep<11>2014
17:47 Mar 12, 2018
Jkt 244001
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
E:\FR\FM\13MRN1.SGM
13MRN1
Federal Register / Vol. 83, No. 49 / Tuesday, March 13, 2018 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2018–05000 Filed 3–12–18; 8:45 am]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Utilization of
Adequate Provision Among Low to
Non-Internet Users
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Food and Drug Administration
[Docket No. FDA–2017–N–0493]
AGENCY:
ACTION:
[CDC–2017–0114; Docket Number NIOSH–
305]
Final National Occupational Research
Agenda for Transportation,
Warehousing and Utilities
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
AGENCY:
ACTION:
Notice of availability.
NIOSH announces the
availability of the final National
Occupational Research Agenda for
Transportation, Warehousing and
Utilities
SUMMARY:
The final document was
published on March 7, 2018.
DATES:
The document may be
obtained at the following link: https://
www.cdc.gov/niosh/nora/sectors/twu/
agenda.html
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Emily Novicki, M.A., M.P.H,
(NORACoordinator@cdc.gov), National
Institute for Occupational Safety and
Health, Centers for Disease Control and
Prevention, Mailstop E–20, 1600 Clifton
Road NE, Atlanta, GA 30329, phone
(404) 498–2581 (not a toll free number).
On
December 1, 2017, NIOSH published a
request for public review in the Federal
Register [82 FR 56973] of the draft
version of the National Occupational
Research Agenda for Transportation,
Warehousing and Utilities. No
comments were received.
amozie on DSK30RV082PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Dated: March 8, 2018.
Frank Hearl,
Chief of Staff, National Institute for
Occupational Safety and Health, Centers for
Disease Control and Prevention.
[FR Doc. 2018–04988 Filed 3–12–18; 8:45 am]
BILLING CODE 4163–19–P
VerDate Sep<11>2014
17:47 Mar 12, 2018
Jkt 244001
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Submit either electronic or
written comments on the collection of
information by April 12, 2018.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910-New and
title ‘‘Utilization of Adequate Provision
Among Low to Non-internet Users.’’
Also include the FDA docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–7726, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
In compliance with 44 U.S.C. 3507,
FDA has submitted the following
proposed collection of information to
OMB for review and clearance.
Utilization of Adequate Provision
Among Low to Non-Internet Users
OMB Control Number 0910–NEW
Section 1701(a)(4) of the Public
Health Service Act (42 U.S.C.
300u(a)(4)) authorizes FDA to conduct
research relating to health information.
Section 1003(d)(2)(C) of the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 393(d)(2)(C)) authorizes
FDA to conduct research relating to
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
10855
drugs and other FDA regulated products
in carrying out the provisions of the
FD&C Act.
Prescription drug advertising
regulations require that broadcast
advertisements containing product
claims present the product’s major side
effects and contraindications in either
audio or audio and visual parts of the
advertisement (21 CFR 202.1(e)(1)); this
is often called the major statement. The
regulations also require that broadcast
advertisements contain a brief summary
of all necessary information related to
side effects and contraindications or
that ‘‘adequate provision’’ be made for
dissemination of the approved package
labeling in connection with the
broadcast (§ 202.1(e)(1)). The
requirement for adequate provision is
generally fulfilled when a firm gives
consumers the option of obtaining FDArequired labeling or other information
via a toll-free telephone number,
through print advertisements or product
brochures, through information
disseminated at health care provider
offices or pharmacies, and through the
internet (Ref. 1). The purpose of
including all four elements is to ensure
that most of a potentially diverse
audience can access the information.
Internet accessibility is increasing, but
many members of certain demographic
groups (e.g., older adults, low
socioeconomic status individuals)
nonetheless report that the internet is
inaccessible to them either as a resource
or due to limited knowledge, and so a
website alone may not adequately serve
all potential audiences (Refs. 2 and 3).
Similarly, some consumers may prefer
to consult sources other than a health
care provider to conduct initial
research, for privacy reasons or
otherwise (Refs. 1, 4, and 5). In light of
these considerations, the toll-free
number and print ad may provide
special value to consumers who are low
to non-internet users and/or those who
value privacy when conducting initial
research on a medication, though not
necessarily unique value relative to one
another. As such, a primary purpose of
this research is to examine the value of
including both the toll-free number and
print ad as part of adequate provision in
direct-to-consumer (DTC) prescription
drug broadcast ads. We will also
investigate the ability and willingness of
low to non-internet users to make use of
internet resources if other options were
unavailable. These questions will be
assessed using a survey methodology
administered via telephone.
In addition, building on concurrent
FDA research regarding drug risk
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 83, Number 49 (Tuesday, March 13, 2018)]
[Notices]
[Pages 10853-10855]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-05000]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-2018-1091; Docket No. CDC-2018-0022]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled ''Using Qualitative Methods to
Understand Issues in HIV Prevention, Care and Treatment in the United
States.'' CDC's goal for this generic information collection mechanism
is to conduct qualitative studies to quickly identify barriers and
facilitators to HIV prevention, care and treatment in specific regions
with high HIV burden in the US.
DATES: CDC must receive written comments on or before May 14, 2018.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2018-
0022 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Leroy A. Richardson, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments through the Federal
eRulemaking portal (regulations.gov) or by U.S. mail to the address
listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Leroy A. Richardson, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road, NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email:
[email protected].
SUPPLEMENTARY INFORMATION:
Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-
3520), Federal agencies must obtain approval from the Office of
Management and Budget (OMB) for each collection of information they
conduct or sponsor. In addition, the PRA also requires Federal agencies
to provide a 60-day notice in the Federal Register concerning each
proposed collection of information, including each new proposed
collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected; and
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses.
5. Assess information collection costs.
Proposed Project
Using Qualitative Methods to Understand Issues in HIV Prevention,
Care and Treatment in the United States (OMB Control Number 0920-1091;
expires 12/31/2018)--Extension--National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention, Centers for Disease Control and
Prevention (CDC).
[[Page 10854]]
Background and Brief Description
The CDC's National Center on HIV/AIDS, Viral Hepatitis, STD and TB
Prevention (NCHHSTP), Division of HIV/AIDS Prevention (DHAP) seeks a
three-year extension to conduct qualitative studies to quickly identify
barriers and facilitators to HIV prevention, care and treatment in
specific regions with high HIV burden in the US. Proposed activities
remain consistent with the national HIV prevention goals, the CDC
Division of HIV/AIDS Prevention (DHAP) Strategic Plan, and DHAP's High-
impact HIV Prevention approach.
The purposes for each data collection study supported under this
umbrella generic information collection plan will be to understand
specific barriers and facilitators to local HIV prevention, care and
treatment in the United States and territories. For example, each study
will seek to identify ways to improve programmatic activities along the
continuum of HIV prevention, treatment and care for different
populations residing in different geographic settings with greatest
burden of HIV.
The target populations for the studies include, but are not limited
to: (1) Persons living with HIV who are in treatment; (2) persons
living with HIV who are out of treatment and who may or may not be
seeking treatment at healthcare facilities; (3) persons at high risk
for HIV acquisition (HIV negative) and HIV transmission (HIV positive);
(4) persons from groups at high risk for HIV including gay, bisexual
and other MSM, transgender persons, and injection and non-injection
drug users; (5) persons from racial and ethnic minorities; and (6)
healthcare providers or other professionals who provide HIV prevention,
care and treatment services. Other populations may include individuals
who provide non-HIV services or otherwise interact with persons living
with HIV or persons at risk for HIV acquisition.
Studies will only provide local contextual information about the
barriers and facilitators to HIV prevention, care, and treatment
experienced by specific communities at risk for acquiring HIV
infection, by HIV-positive persons across the HIV care continuum, and
by organizations or individuals providing HIV prevention, care,
treatment, and related support services.
Data collection methods used in any of the specific studies
primarily will consist of rapid qualitative assessment methodologies,
such as semi-structured and in-depth qualitative interviews, focus
groups; direct observations; document reviews; and short structured
surveys. Data will be analyzed using well-established qualitative
analysis methods, such as coding interviews for themes about barriers
and successes to HIV prevention, care, and treatment. Structured
response surveys will be analyzed using descriptive statistics and
other appropriate statistical methods.
CDC will use the results from each specific data collection study
to help identify ways to improve local programmatic activities for
specific communities along the continuum of HIV prevention, treatment
and care for populations and areas with the greatest HIV burden. CDC
will communicate study outcomes to local stakeholders and organizations
in positions to consider and implement site-specific improvements in
HIV prevention, care, and treatment for each of the study sites
examined. For stakeholders, organizations, or agencies outside the
local affected communities, all communications will include clear
discussion of the limitations of the region-specific, qualitative
methods and the non-generalizability of the study outcomes.
For a given year, each separate data collection will range from 30
(minimum) to 200 (maximum) respondents, based on the nature and scope
of the research purposes. For example, if there are three data
collections, the maximum combined number of expected respondents is
600. In a given year, CDC anticipates the need to screen 1,600 persons
to identify 800 eligible persons, of which 600 persons will agree to
participate.
CDC anticipates that screener forms will take 5 minutes to complete
each, contact information forms will take 1 minute to complete each,
and consent forms will take 5 minutes to complete each. CDC anticipates
study eligibility for 50 percent of the targeted populations screened.
Of eligible persons, 75% will agree to participate.
Brief structured surveys will take 15 minutes to complete. In-depth
interviews or focus groups with respondents are expected to take 60
minutes (1 hour) to complete. In-depth interviews or focus groups with
healthcare providers are expected to take 45 minutes to complete.
The total annual response burden, based on an average of 600 study
respondents per year (assuming three large data collections involving
200 participants each), is 918 hours.
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
General Public--Adults........ Study Screener.. 1,600 1 5/60 133
General Public--Adults........ Contact 600 1 1/60 10
Information
Form.
General Public--Adults........ Consent Form.... 600 1 5/60 50
General Public--Adults........ Demographic 500 1 15/60 125
Survey.
General Public--Adults........ Interview Guide. 500 1 1 500
General Public--Adults........ Provider 100 1 15/60 25
Demographic
Survey.
General Public--Adults........ Provider 100 1 45/60 75
Interview Guide.
---------------
Total..................... ................ .............. .............. .............. 918
----------------------------------------------------------------------------------------------------------------
[[Page 10855]]
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2018-05000 Filed 3-12-18; 8:45 am]
BILLING CODE 4163-18-P
